{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:23:54Z","timestamp":1783646634881,"version":"3.55.0"},"publisher-location":"New York, NY","reference-count":34,"publisher":"Springer US","isbn-type":[{"value":"9781071648063","type":"print"},{"value":"9781071648070","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026]]},"DOI":"10.1007\/978-1-0716-4807-0_20","type":"book-chapter","created":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T09:27:50Z","timestamp":1763803670000},"page":"239-248","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Phase 1\/2a Clinical Trial Protocol for Lentiviral Vector-Based Retinal Gene Therapy to Slow the Progression of Retinitis Pigmentosa"],"prefix":"10.1007","author":[{"given":"Takahiro","family":"Hisai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kohji","family":"Kusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Kobayakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,23]]},"reference":[{"issue":"9549","key":"20_CR1","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/S0140-6736(06)69740-7","volume":"368","author":"DT Hartong","year":"2006","unstructured":"Hartong DT, Berson EL, Dryja TP (2006) Retinitis pigmentosa. Lancet 368(9549):1795\u20131809. https:\/\/doi.org\/10.1016\/S0140-6736(06)69740-7","journal-title":"Lancet"},{"issue":"3","key":"20_CR2","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s10384-023-00986-9","volume":"67","author":"R Matoba","year":"2023","unstructured":"Matoba R, Morimoto N, Kawasaki R et al (2023) A nationwide survey of newly certified visually impaired individuals in Japan for the fiscal year 2019: impact of the revision of criteria for visual impairment certification. Jpn J Ophthalmol 67(3):346\u2013352. https:\/\/doi.org\/10.1007\/s10384-023-00986-9","journal-title":"Jpn J Ophthalmol"},{"issue":"4","key":"20_CR3","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s10384-024-01068-0","volume":"68","author":"G Mawatari","year":"2024","unstructured":"Mawatari G, Hiwatashi S, Motani T et al (2024) Efficacy of a wearable night-vision aid in patients with concentric peripheral visual field loss: a randomized, crossover trial. Jpn J Ophthalmol 68(4):321\u2013326. https:\/\/doi.org\/10.1007\/s10384-024-01068-0","journal-title":"Jpn J Ophthalmol"},{"key":"20_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.preteyeres.2017.10.004","volume":"63","author":"MF Dias","year":"2018","unstructured":"Dias MF, Joo K, Kemp JA et al (2018) Molecular genetics and emerging therapies for retinitis pigmentosa: basic research and clinical perspectives. Prog Retin Eye Res 63:107\u2013131. https:\/\/doi.org\/10.1016\/j.preteyeres.2017.10.004","journal-title":"Prog Retin Eye Res"},{"issue":"10097","key":"20_CR5","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","volume":"390","author":"S Russell","year":"2017","unstructured":"Russell S, Bennett J, Wellman JA et al (2017) Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet 390(10097):849\u2013860. https:\/\/doi.org\/10.1016\/S0140-6736(17)31868-8","journal-title":"Lancet"},{"issue":"10","key":"20_CR6","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1016\/j.ophtha.2021.03.031","volume":"128","author":"AM Maguire","year":"2021","unstructured":"Maguire AM, Russell S, Chung DC et al (2021) Durability of Voretigene Neparvovec for Biallelic RPE65-mediated inherited retinal disease: phase 3 results at 3 and 4 years. Ophthalmology 128(10):1460\u20131468. https:\/\/doi.org\/10.1016\/j.ophtha.2021.03.031","journal-title":"Ophthalmology"},{"issue":"9","key":"20_CR7","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.ophtha.2024.02.023","volume":"131","author":"BL Lam","year":"2024","unstructured":"Lam BL, Pennesi ME, Kay CN et al (2024) Assessment of visual function with Cotoretigene Toliparvovec in X-linked retinitis Pigmentosa in the randomized XIRIUS phase 2\/3 study. Ophthalmology 131(9):1083\u20131093. https:\/\/doi.org\/10.1016\/j.ophtha.2024.02.023","journal-title":"Ophthalmology"},{"issue":"21","key":"20_CR8","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1056\/NEJMoa2309915","volume":"390","author":"EA Pierce","year":"2024","unstructured":"Pierce EA, Aleman TS, Jayasundera KT et al (2024) Gene editing for CEP290-associated retinal degeneration. N Engl J Med 390(21):1972\u20131984. https:\/\/doi.org\/10.1056\/NEJMoa2309915","journal-title":"N Engl J Med"},{"issue":"9967","key":"20_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/S0140-6736(14)61376-3","volume":"385","author":"SD Schwartz","year":"2015","unstructured":"Schwartz SD, Regillo CD, Lam BL et al (2015) Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt\u2019s macular dystrophy: follow-up of two open-label phase 1\/2 studies. Lancet 385(9967):509\u2013516. https:\/\/doi.org\/10.1016\/S0140-6736(14)61376-3","journal-title":"Lancet"},{"issue":"1","key":"20_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s13287-017-0661-8","volume":"8","author":"Y Liu","year":"2017","unstructured":"Liu Y, Chen SJ, Li SY et al (2017) Long-term safety of human retinal progenitor cell transplantation in retinitis pigmentosa patients. Stem Cell Res Ther 8(1):209. https:\/\/doi.org\/10.1186\/s13287-017-0661-8","journal-title":"Stem Cell Res Ther"},{"issue":"12","key":"20_CR11","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/j.stem.2023.11.004","volume":"30","author":"Y Hirami","year":"2023","unstructured":"Hirami Y, Mandai M, Sugita S et al (2023) Safety and stable survival of stem-cell-derived retinal organoid for 2 years in patients with retinitis pigmentosa. Cell Stem Cell 30(12):1585\u20131596 e1586. https:\/\/doi.org\/10.1016\/j.stem.2023.11.004","journal-title":"Cell Stem Cell"},{"issue":"8","key":"20_CR12","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/s00417-023-05986-6","volume":"261","author":"AD Dave","year":"2023","unstructured":"Dave AD, Chen KG, Chiang TT et al (2023) Oral minocycline for the treatment of retinitis pigmentosa-associated cystoid macular edema: results of a phase I\/II clinical trial. Graefes Arch Clin Exp Ophthalmol 261(8):2209\u20132220. https:\/\/doi.org\/10.1007\/s00417-023-05986-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"4","key":"20_CR13","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.survophthal.2004.04.003","volume":"49","author":"RK Koenekoop","year":"2004","unstructured":"Koenekoop RK (2004) An overview of Leber congenital amaurosis: a model to understand human retinal development. Surv Ophthalmol 49(4):379\u2013398. https:\/\/doi.org\/10.1016\/j.survophthal.2004.04.003","journal-title":"Surv Ophthalmol"},{"issue":"3","key":"20_CR14","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s12325-021-02036-7","volume":"39","author":"JMF Sallum","year":"2022","unstructured":"Sallum JMF, Kaur VP, Shaikh J et al (2022) Epidemiology of mutations in the 65-kDa retinal pigment epithelium (RPE65) gene-mediated inherited retinal dystrophies: a systematic literature review. Adv Ther 39(3):1179\u20131198. https:\/\/doi.org\/10.1007\/s12325-021-02036-7","journal-title":"Adv Ther"},{"issue":"4","key":"20_CR15","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1073\/pnas.90.4.1526","volume":"90","author":"FR Steele","year":"1993","unstructured":"Steele FR, Chader GJ, Johnson LV et al (1993) Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Natl Acad Sci USA 90(4):1526\u20131530. https:\/\/doi.org\/10.1073\/pnas.90.4.1526","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6","key":"20_CR16","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1046\/j.1471-4159.1995.64062509.x","volume":"64","author":"T Taniwaki","year":"1995","unstructured":"Taniwaki T, Becerra SP, Chader GJ et al (1995) Pigment epithelium-derived factor is a survival factor for cerebellar granule cells in culture. J Neurochem 64(6):2509\u20132517. https:\/\/doi.org\/10.1046\/j.1471-4159.1995.64062509.x","journal-title":"J Neurochem"},{"issue":"8","key":"20_CR17","first-page":"1700","volume":"30","author":"J Tombran-Tink","year":"1989","unstructured":"Tombran-Tink J, Johnson LV (1989) Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells. Invest Ophthalmol Vis Sci 30(8):1700\u20131707","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5425","key":"20_CR18","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1126\/science.285.5425.245","volume":"285","author":"DW Dawson","year":"1999","unstructured":"Dawson DW, Volpert OV, Gillis P et al (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285(5425):245\u2013248. https:\/\/doi.org\/10.1126\/science.285.5425.245","journal-title":"Science"},{"issue":"4","key":"20_CR19","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/nrc3484","volume":"13","author":"SP Becerra","year":"2013","unstructured":"Becerra SP, Notario V (2013) The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential. Nat Rev Cancer 13(4):258\u2013271. https:\/\/doi.org\/10.1038\/nrc3484","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"20_CR20","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1016\/j.ajo.2003.11.080","volume":"137","author":"N Ogata","year":"2004","unstructured":"Ogata N, Matsuoka M, Imaizumi M et al (2004) Decreased levels of pigment epithelium-derived factor in eyes with neuroretinal dystrophic diseases. Am J Ophthalmol 137(6):1129\u20131130. https:\/\/doi.org\/10.1016\/j.ajo.2003.11.080","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"20_CR21","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.2353\/ajpath.2008.080466","volume":"173","author":"Y Murakami","year":"2008","unstructured":"Murakami Y, Ikeda Y, Yonemitsu Y et al (2008) Inhibition of nuclear translocation of apoptosis-inducing factor is an essential mechanism of the neuroprotective activity of pigment epithelium-derived factor in a rat model of retinal degeneration. Am J Pathol 173(5):1326\u20131338. https:\/\/doi.org\/10.2353\/ajpath.2008.080466","journal-title":"Am J Pathol"},{"key":"20_CR22","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.exer.2019.04.008","volume":"184","author":"A Hernandez-Pinto","year":"2019","unstructured":"Hernandez-Pinto A, Polato F, Subramanian P et al (2019) PEDF peptides promote photoreceptor survival in rd10 retina models. Exp Eye Res 184:24\u201329. https:\/\/doi.org\/10.1016\/j.exer.2019.04.008","journal-title":"Exp Eye Res"},{"issue":"5","key":"20_CR23","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.neuron.2019.02.017","volume":"101","author":"E Hudry","year":"2019","unstructured":"Hudry E, Vandenberghe LH (2019) Therapeutic AAV gene transfer to the nervous system: a clinical reality. Neuron 101(5):839\u2013862. https:\/\/doi.org\/10.1016\/j.neuron.2019.02.017","journal-title":"Neuron"},{"key":"20_CR24","doi-asserted-by":"publisher","first-page":"0291","DOI":"10.34133\/research.0291","volume":"6","author":"X He","year":"2023","unstructured":"He X, Fu Y, Ma L et al (2023) AAV for gene therapy in ocular diseases: Progress and prospects. Research (Wash D C) 6:0291. https:\/\/doi.org\/10.34133\/research.0291","journal-title":"Research (Wash D C)"},{"issue":"12","key":"20_CR25","doi-asserted-by":"publisher","first-page":"5785","DOI":"10.1073\/pnas.1821000116","volume":"116","author":"W Xiong","year":"2019","unstructured":"Xiong W, Wu DM, Xue Y et al (2019) AAV cis-regulatory sequences are correlated with ocular toxicity. Proc Natl Acad Sci USA 116(12):5785\u20135794. https:\/\/doi.org\/10.1073\/pnas.1821000116","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"20_CR26","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1089\/hum.2018.144","volume":"29","author":"H Khabou","year":"2018","unstructured":"Khabou H, Cordeau C, Pacot L et al (2018) Dosage thresholds and influence of transgene cassette in adeno-associated virus-related toxicity. Hum Gene Ther 29(11):1235\u20131241. https:\/\/doi.org\/10.1089\/hum.2018.144","journal-title":"Hum Gene Ther"},{"issue":"3","key":"20_CR27","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","volume":"26","author":"J Cehajic-Kapetanovic","year":"2020","unstructured":"Cehajic-Kapetanovic J, Xue K, Martinez-Fernandez de la Camara C et al (2020) Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. Nat Med 26(3):354\u2013359. https:\/\/doi.org\/10.1038\/s41591-020-0763-1","journal-title":"Nat Med"},{"issue":"1","key":"20_CR28","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.oret.2021.03.016","volume":"6","author":"WS Gange","year":"2022","unstructured":"Gange WS, Sisk RA, Besirli CG et al (2022) Perifoveal Chorioretinal atrophy after subretinal Voretigene Neparvovec-rzyl for RPE65-mediated Leber congenital Amaurosis. Ophthalmol Retina 6(1):58\u201364. https:\/\/doi.org\/10.1016\/j.oret.2021.03.016","journal-title":"Ophthalmol Retina"},{"issue":"13","key":"20_CR29","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1089\/10430340050129486","volume":"11","author":"T Nakajima","year":"2000","unstructured":"Nakajima T, Nakamaru K, Ido E et al (2000) Development of novel simian immunodeficiency virus vectors carrying a dual gene expression system. Hum Gene Ther 11(13):1863\u20131874. https:\/\/doi.org\/10.1089\/10430340050129486","journal-title":"Hum Gene Ther"},{"issue":"14","key":"20_CR30","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/sj.gt.3301973","volume":"10","author":"Y Ikeda","year":"2003","unstructured":"Ikeda Y, Goto Y, Yonemitsu Y et al (2003) Simian immunodeficiency virus-based lentivirus vector for retinal gene transfer: a preclinical safety study in adult rats. Gene Ther 10(14):1161\u20131169. https:\/\/doi.org\/10.1038\/sj.gt.3301973","journal-title":"Gene Ther"},{"issue":"9","key":"20_CR31","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1089\/hum.2009.048","volume":"20","author":"Y Ikeda","year":"2009","unstructured":"Ikeda Y, Yonemitsu Y, Miyazaki M et al (2009) Acute toxicity study of a simian immunodeficiency virus-based lentiviral vector for retinal gene transfer in nonhuman primates. Hum Gene Ther 20(9):943\u2013954. https:\/\/doi.org\/10.1089\/hum.2009.048","journal-title":"Hum Gene Ther"},{"issue":"17","key":"20_CR32","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1038\/sj.gt.3302028","volume":"10","author":"M Miyazaki","year":"2003","unstructured":"Miyazaki M, Ikeda Y, Yonemitsu Y et al (2003) Simian lentiviral vector-mediated retinal gene transfer of pigment epithelium-derived factor protects retinal degeneration and electrical defect in Royal College of surgeons rats. Gene Ther 10(17):1503\u20131511. https:\/\/doi.org\/10.1038\/sj.gt.3302028","journal-title":"Gene Ther"},{"key":"20_CR33","doi-asserted-by":"publisher","unstructured":"Li X, Le Y, Zhang Z et al (2023) Viral vector-based gene therapy. Int J Mol Sci 24(9). https:\/\/doi.org\/10.3390\/ijms24097736","DOI":"10.3390\/ijms24097736"},{"issue":"6","key":"20_CR34","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1089\/hum.2009.009","volume":"20","author":"Y Ikeda","year":"2009","unstructured":"Ikeda Y, Yonemitsu Y, Miyazaki M et al (2009) Stable retinal gene expression in nonhuman primates via subretinal injection of SIVagm-based lentiviral vectors. Hum Gene Ther 20(6):573\u2013579. https:\/\/doi.org\/10.1089\/hum.2009.009","journal-title":"Hum Gene Ther"}],"container-title":["Methods in Molecular Biology","Lentiviral Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-1-0716-4807-0_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T15:58:12Z","timestamp":1779551892000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-1-0716-4807-0_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,23]]},"ISBN":["9781071648063","9781071648070"],"references-count":34,"URL":"https:\/\/doi.org\/10.1007\/978-1-0716-4807-0_20","relation":{},"ISSN":["1064-3745","1940-6029"],"issn-type":[{"value":"1064-3745","type":"print"},{"value":"1940-6029","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,23]]},"assertion":[{"value":"23 November 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}